CA2275438A1 - Methodes ameliorees de transduction cellulaire - Google Patents
Methodes ameliorees de transduction cellulaire Download PDFInfo
- Publication number
- CA2275438A1 CA2275438A1 CA002275438A CA2275438A CA2275438A1 CA 2275438 A1 CA2275438 A1 CA 2275438A1 CA 002275438 A CA002275438 A CA 002275438A CA 2275438 A CA2275438 A CA 2275438A CA 2275438 A1 CA2275438 A1 CA 2275438A1
- Authority
- CA
- Canada
- Prior art keywords
- cell
- cells
- composition
- tumor
- interferon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Compositions et méthodes pour inhiber l'expression et/ou l'activité de l'interféron-.beta. endogène dans des cellules ciblées pour une transduction avec des vecteurs viraux, en particulier avec des vecteurs d'adénovirus. L'invention concerne par conséquent également des méthodes de thérapie génique améliorées pour des maladies génétiques. L'invention porte également sur des méthodes de traitement des maladies liées à une néovascularisation, par exemple le cancer, par la production in vivo d'angiostatine inhibant la formation nouveaux vaisseaux sanguins. Dans des modes de réalisation particuliers, ce résultat est obtenu par transduction de macrophages ex vivo avec un gène GM-CSF, induisant la sécrétion de métallo-élastase de macrophage, laquelle convertit le plasminogène en angiostatine. Une fois administrés, les macrophages transduits se dirigent naturellement vers les sites tumoraux, réalisant un ciblage efficace de l'effet thérapeutique.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3133096P | 1996-11-20 | 1996-11-20 | |
US60/031,330 | 1996-11-20 | ||
PCT/US1997/021475 WO1998022605A1 (fr) | 1996-11-20 | 1997-11-19 | Methodes ameliorees de transduction cellulaire |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2275438A1 true CA2275438A1 (fr) | 1998-05-28 |
Family
ID=21858846
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002275438A Abandoned CA2275438A1 (fr) | 1996-11-20 | 1997-11-19 | Methodes ameliorees de transduction cellulaire |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0963440A4 (fr) |
JP (1) | JP2001505205A (fr) |
CA (1) | CA2275438A1 (fr) |
WO (1) | WO1998022605A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004016021A (ja) | 2002-06-12 | 2004-01-22 | Japan Science & Technology Corp | 抗体および阻害剤並びにそれを用いた形質転換方法および形質転換キット |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4987071A (en) * | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
US5656465A (en) * | 1994-05-04 | 1997-08-12 | Therion Biologics Corporation | Methods of in vivo gene delivery |
DE4442587A1 (de) * | 1994-11-30 | 1996-08-01 | Boehringer Ingelheim Int | Verfahren zum Einbringen von Fremdmaterial in höhere eukaryotische Zellen |
US5626862A (en) * | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
US5552309A (en) * | 1994-09-30 | 1996-09-03 | Indiana University Foundation | Use of polyols for improving the introduction of genetic material into cells |
-
1997
- 1997-11-19 JP JP52395398A patent/JP2001505205A/ja active Pending
- 1997-11-19 WO PCT/US1997/021475 patent/WO1998022605A1/fr not_active Application Discontinuation
- 1997-11-19 CA CA002275438A patent/CA2275438A1/fr not_active Abandoned
- 1997-11-19 EP EP97950669A patent/EP0963440A4/fr not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP0963440A1 (fr) | 1999-12-15 |
WO1998022605A1 (fr) | 1998-05-28 |
EP0963440A4 (fr) | 2004-12-29 |
JP2001505205A (ja) | 2001-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2518150C (fr) | Procedes et compositions impliquant mda-7 | |
Zhang et al. | Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer. | |
US20060024780A1 (en) | Wwox: a tumor suppressor gene mutated in multiple cancers | |
JP2005533000A (ja) | Mda−7に関与する免疫誘導を増強する方法 | |
CN101905024A (zh) | 含有血管生成素-样蛋白质3angptl3的组合物及其使用方法 | |
US6251871B1 (en) | P16 expression constructs and their application in cancer therapy | |
US5980886A (en) | Recombinant vectors for reconstitution of liver | |
AU2001267058A1 (en) | Aav vector-based compositions and therapeutic uses thereof | |
WO1998037185A2 (fr) | Vecteurs pour expression genique regulee | |
JP2006094863A (ja) | ケモカインα−5 | |
AU762493B2 (en) | Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery | |
CA2429769C (fr) | Procedes de traitement mettant en application mda-7 humain | |
WO2002006344A2 (fr) | Compositions et procedes a base des proteines vespides et pathogenes associees a des proteines specifiques aux testicules (rtvp) pour le traitement du cancer prostatique | |
US6517828B1 (en) | C-CAM as an angiogenesis inhibitor | |
CA2275438A1 (fr) | Methodes ameliorees de transduction cellulaire | |
US7052692B1 (en) | Role of tyrosine phosphorylation of a cellular protein in adeno-associated virus 2-mediated transgene expression | |
WO1998022605A9 (fr) | Methodes ameliorees de transduction cellulaire | |
US6331284B1 (en) | P202 is a tumor suppressor | |
US20060194319A1 (en) | Promoter substitution for immunoglobulin therapy | |
US20010036929A1 (en) | Xrcc3 is required for assembly of Rad51-complexes in vivo | |
US20020169126A1 (en) | Compositions and methods for inactivating the Akt oncogene and/or activating the p38 pro-apoptotic gene | |
WO1999011652A1 (fr) | Role de la phosphorylation de la tyrosine d'une proteine cellulaire dans l'expression d'un transgene induit par deux genes d'un virus associe a un adenovirus | |
AU4435002A (en) | Modified retinoblastoma tumor suppressor proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |